Anixa Biosciences Set to Shine at H.C. Wainwright Global Investment Conference
Anixa Biosciences, Inc., a pioneering biotechnology company specializing in cancer treatment and prevention, has announced its participation in the highly anticipated H.C. Wainwright 27th Annual Global Investment Conference. This event is scheduled to take place from September 8 to 10, 2025, at the luxurious Lotte New York Palace Hotel located in New York City. The company’s President and CFO, Mike Catelani, will deliver a keynote presentation on September 8 at 4:30 PM ET, during which he will also be available for one-on-one meetings with investors, analysts, and potential collaborators.
Anixa’s mission is centered around the development of innovative therapies aimed at combating cancer, specifically through their advanced research into immunotherapy. The company is widely recognized for its unique approach to cancer treatment, particularly the ovarian cancer immunotherapy program developed in partnership with the Moffitt Cancer Center. This groundbreaking initiative leverages a novel CAR-T technology, termed chimeric endocrine receptor-T cell (CER-T) technology, which distinguishes itself from traditional therapies by targeting tumor cells more effectively.
In addition to the ovarian cancer program, Anixa's diverse therapeutic portfolio includes vaccines developed in collaboration with the esteemed Cleveland Clinic aimed at preventing and treating breast and ovarian cancers. These vaccine candidates are designed to utilize the body's own immune response to fight against specific proteins typically expressed in certain cancers.
The collaboration with Moffitt Cancer Center allows Anixa to tap into the cutting-edge research and expertise which has historically led to important breakthroughs in cancer immunotherapy. The Moffitt Cancer Center is recognized as a leader in the field, paving the way for next-generation therapies including CAR-T and tumor-infiltrating lymphocytes (TILs) that capitalize on the immune response to eliminate cancerous cells.
During the investment conference, the presentation by Mike Catelani will focus on Anixa's strategic vision, progress in its pipeline, and how partnerships with leading research institutions position the company favorably within the rapidly evolving biotechnology landscape. Investors will gain insights into Anixa’s business model, which emphasizes collaborations at every phase of product development, helping it stay ahead of emerging technologies in related fields.
As the conference nears, anticipation builds for Anixa's insights and updates regarding both their existing and upcoming projects. This event not only symbolizes Anixa's commitment to innovation but also marks an opportunity to establish connections that could advance these life-saving therapies into broader clinical applications. Interested parties are encouraged to attend the presentation, and details for a live webcast can be found on the company’s official website. Anixa continues to push the boundaries of cancer treatment, striving to provide new hope for patients worldwide.
For further information about Anixa and its groundbreaking initiatives, visit their official website or follow them on LinkedIn, X, Facebook, and YouTube, where they share updates on their research and development efforts along with invaluable insights into cancer therapy advancements.
Anixa’s mission is centered around the development of innovative therapies aimed at combating cancer, specifically through their advanced research into immunotherapy. The company is widely recognized for its unique approach to cancer treatment, particularly the ovarian cancer immunotherapy program developed in partnership with the Moffitt Cancer Center. This groundbreaking initiative leverages a novel CAR-T technology, termed chimeric endocrine receptor-T cell (CER-T) technology, which distinguishes itself from traditional therapies by targeting tumor cells more effectively.
In addition to the ovarian cancer program, Anixa's diverse therapeutic portfolio includes vaccines developed in collaboration with the esteemed Cleveland Clinic aimed at preventing and treating breast and ovarian cancers. These vaccine candidates are designed to utilize the body's own immune response to fight against specific proteins typically expressed in certain cancers.
The collaboration with Moffitt Cancer Center allows Anixa to tap into the cutting-edge research and expertise which has historically led to important breakthroughs in cancer immunotherapy. The Moffitt Cancer Center is recognized as a leader in the field, paving the way for next-generation therapies including CAR-T and tumor-infiltrating lymphocytes (TILs) that capitalize on the immune response to eliminate cancerous cells.
During the investment conference, the presentation by Mike Catelani will focus on Anixa's strategic vision, progress in its pipeline, and how partnerships with leading research institutions position the company favorably within the rapidly evolving biotechnology landscape. Investors will gain insights into Anixa’s business model, which emphasizes collaborations at every phase of product development, helping it stay ahead of emerging technologies in related fields.
As the conference nears, anticipation builds for Anixa's insights and updates regarding both their existing and upcoming projects. This event not only symbolizes Anixa's commitment to innovation but also marks an opportunity to establish connections that could advance these life-saving therapies into broader clinical applications. Interested parties are encouraged to attend the presentation, and details for a live webcast can be found on the company’s official website. Anixa continues to push the boundaries of cancer treatment, striving to provide new hope for patients worldwide.
For further information about Anixa and its groundbreaking initiatives, visit their official website or follow them on LinkedIn, X, Facebook, and YouTube, where they share updates on their research and development efforts along with invaluable insights into cancer therapy advancements.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.